Johnson & Johnson (JNJ)

Quick facts

Marketed products

• Darzalex · Oncology · revenue 11800
  Daratumumab binds CD38 on tumor cells, inducing apoptosis and immune-mediated lysis via CDC, ADCC, and ADCP.
• Stelara · Immunology · revenue 9500
  Ustekinumab binds to the p40 subunit of IL-12 and IL-23, disrupting their signaling and reducing inflammation.
• Remicade · Oncology · revenue 4200
  Remicade works by binding to and neutralizing tumor necrosis factor, a protein that promotes inflammation and tissue damage.
• Invega Sustenna · Metabolic · revenue 3800
  Invega Sustenna works by blocking a specific channel in the brain that helps regulate electrical activity.
• Tremfya · Immunology · revenue 3600
  Guselkumab binds to IL-23's p19 subunit, blocking its interaction with the IL-23 receptor and inhibiting proinflammatory cytokine release.
• Erleada · Oncology · revenue 2600
  Erleada blocks the androgen receptor, a protein that helps cancer cells grow.
• Zytiga · Oncology · revenue 1500
  Zytiga blocks the production of male hormones that fuel prostate cancer growth.
• Carvykti · Oncology · revenue 1100
• Rybrevant · Oncology · revenue 800
  Amivantamab-vmjw targets EGFR and MET, disrupting their signaling and enhancing immune cell-mediated destruction of tumor cells.
• Invokana · Metabolic · revenue 800
  Invokana works by blocking the SGLT2 protein in the kidneys to reduce glucose reabsorption.
• Spravato · Metabolic · revenue 800
  Spravato works by blocking the action of glutamate, a neurotransmitter involved in mood regulation.
• Sirturo · Infectious Disease · revenue 400
  Sirturo works by blocking the potassium voltage-gated channel subfamily H member 2, which is essential for the survival of Mycobacterium tuberculosis bacteria.
• Talvey · Oncology · revenue 400
  Talquetamab binds to the T-cell surface glycoprotein CD3, triggering a response that kills cancer cells.
• Bcmaxcd3 · Oncology · revenue 400
  Teclistamab-cqyv activates T-cells by binding to CD3 and BCMA, leading to the lysis of multiple myeloma cells.
• Balversa · Oncology · revenue 300
  Balversa works by blocking the fibroblast growth factor receptor 1, a protein that helps cancer cells grow and spread.
• Reopro · Cardiovascular
• Axert · Neuroscience
  Axert works by binding to serotonin receptors in the brain to relieve migraine pain.
• RYBREVANT · Oncology
• Abiraterone Acetate · Oncology
  Abiraterone Acetate blocks the production of androgens, which are hormones that prostate cancer cells need to grow.
• Parafon Forte Dsc · Pain
• Prezista · Immunology
  Darunavir works by blocking the protease enzyme, which is essential for the replication of the HIV virus.
• Synestrol · Other
• Benadryl · Neuroscience
• Motilium · Cardiovascular
• Intelence · Immunology
  Intelence works by blocking the reverse transcriptase enzyme, which is essential for the replication of the HIV virus.
• Duragesic · Oncology
  Synthetic opioid 50-100x more potent than morphine that binds mu-opioid receptors, providing potent analgesia and anesthesia.
• Razadyne · Neuroscience
  Razadyne works by blocking the enzyme that breaks down acetylcholine, allowing more of this neurotransmitter to be available in the brain.
• Grifulvin V · Infectious Disease
• GRIFULVIN V · Dermatology
• Haldol · Neuroscience
• Haldol · Neuroscience
• Remicade · Oncology
  Infliximab-dyyb neutralizes TNFα by binding with high affinity to soluble and transmembrane forms, inhibiting receptor binding.
• Nizoral · Infectious Disease
• Imodium · Metabolic
  Peripheral mu-opioid receptor agonist that slows intestinal motility and increases fluid absorption without crossing the blood-brain barrier.
• Meclan · Immunology
• Monistat · Infectious Disease
• Imaavy · Immunology
  Imaavy works by binding to and blocking the activity of certain immune cells that mistakenly attack healthy nerve-muscle connections in people with gMG.
• Micronor · Bone
  ORIAHNN combines elagolix, which suppresses LH and FSH to reduce ovarian sex hormones, with estradiol and norethindrone acetate to mitigate side effects.
• Risperdal · Neuroscience
  Atypical antipsychotic that antagonizes dopamine D2 and serotonin 5-HT2A receptors for schizophrenia and bipolar disorder.
• Xarelto · Oncology
  Selective FXa inhibitor that decreases thrombin generation without requiring cofactors.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Johnson & Johnson portfolio CI brief
• Johnson & Johnson pipeline updates RSS